Adenosine

Generic Name: Adenosine

Brand Names: Adenocard, Viva-drops Lubricating Eye Drops

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₃N_₅O_₄

CAS Number: 58-61-7

Unique Ingredient Identifier: K72T3FS567

Background: The structure of adenosine was first described in 1931, though the vasodilating effects were not described in literature until the 1940s. Adenosine is indicated as an adjunct to thallium-201 in myocardial perfusion scintigraphy, though it is rarely used in this indication, having largely been replaced by dipyridamole and [regadenson]. Adenosine is also indicated in the treatment of supraventricular tachycardia.

Adenosine was granted FDA approval on 30 October 1989.

Indication: Adenosine is indicated as an adjunct to thallium-201 in myocardial perfusion scintigraphy in patients unable to adequately exercise. It is also indicated to convert sinus rhythm of paroxysmal supraventricular tachycardia.

Associated Conditions: Paroxysmal Supraventricular Tachycardia (PSVT), Pulmonary Arterial Hypertension (PAH), SVT, Supraventricular Tachycardia (SVT)

Clinical Trials

A Trial to Compare American Heart Association (AHA) and Simple (SIM)Method to Give Adenosine to Treat Supra-ventricular Tachycardia (SVT)

Phase 3

Completed

Conditions: Supra-ventricular Tachycardia

Interventions: Drug: Adenosine

First Posted Date: 2020-05-18

Last Posted Date: 2021-06-25

Lead Sponsor: University of Pretoria

Target Recruit Count: 30

Registration Number: NCT04392362

Locations: 🇿🇦
Steve Biko hospital, Pretoria, Gauteng, South Africa

Adenosine Versus Verapamil for Management of Supraventricular Tachycardia Post- Coronary Artery Bypass Grafting

Not Applicable

Completed

Conditions: Supraventricular Tachycardia

Interventions: Drug: verapamil
Drug: adenosine

First Posted Date: 2019-12-18

Last Posted Date: 2020-12-02

Lead Sponsor: Ain Shams University

Target Recruit Count: 268

Registration Number: NCT04203368

Locations: 🇪🇬
Ain Shams university, Cairo, Egypt

Pyridoxine, P2 Receptor Antagonism, and ATP-mediated Vasodilation in Young Adults

Early Phase 1

Completed

Conditions: Receptor Blockade

Interventions: Drug: Adenosine Triphosphate
Drug: Adenosine Diphosphate
Drug: Acetylcholine
Drug: Uridine Triphosphate
Drug: Sodium Nitroprusside
Drug: Adenosine Monophosphate
Drug: Adenosine
Drug: Vitamin B 6
Drug: Pyridoxal 5'-Phosphate

First Posted Date: 2018-11-13

Last Posted Date: 2021-07-27

Lead Sponsor: Colorado State University

Target Recruit Count: 9

Registration Number: NCT03738943

Locations: 🇺🇸
Human Performance and Clinical Research Laboratory, Fort Collins, Colorado, United States

Adenosine Contrast CorrELations in Evaluating RevAscularizaTION

Phase 4

Completed

Conditions: Percutaneous Coronary Intervention

Interventions: Drug: Iopamidol
Drug: adenosine
Device: Navvus® Catheter
Device: CVi® Contrast Delivery System

First Posted Date: 2018-06-15

Last Posted Date: 2024-07-05

Lead Sponsor: Duke University

Target Recruit Count: 201

Registration Number: NCT03557385

Locations: 🇺🇸
Long Beach VA, Long Beach, California, United States
🇺🇸
Mercy Hospital, Coon Rapids, Minnesota, United States
🇺🇸
Durham VA, Durham, North Carolina, United States

and more 2 locations

A Single Center Diagnostic, Cross-sectional Study of Coronary Microvascular Dysfunction

Not Applicable

Recruiting

Conditions: Ischemic Heart Disease
Coronary Microvascular Disease
Myocardial Ischemia

Interventions: Drug: Bivalirudin
Drug: Adenosine
Drug: Heparin
Device: Pressure-Temperature Sensor Guidewire
Device: Guiding Catheter

First Posted Date: 2018-05-25

Last Posted Date: 2025-01-10

Lead Sponsor: NYU Langone Health

Target Recruit Count: 175

Registration Number: NCT03537586

Locations: 🇺🇸
New York University School of Medicine, New York, New York, United States

Adenosine and Magnesium Sulphate as Adjuvants for PECS Block.

Not Applicable

Completed

Conditions: Breast Surgery

Interventions: Drug: Bupivacaine 0.25%
Drug: Adenosine 12mg
Drug: Magnesium Sulphate 500 mg

First Posted Date: 2017-11-17

Last Posted Date: 2017-11-17

Lead Sponsor: Menoufia University

Target Recruit Count: 90

Registration Number: NCT03344679

Adenosine and A2A Receptors in Human Brown Adipose Tissue

Not Applicable

Completed

Conditions: Obesity

Interventions: Other: Cold exposure
Drug: Adenosine

First Posted Date: 2017-10-31

Last Posted Date: 2017-11-06

Lead Sponsor: Turku University Hospital

Target Recruit Count: 11

Registration Number: NCT03327168

Microvascular Dysfunction in Nonischemic Cardiomyopathy: Insights From CMR Assessment of Coronary Flow Reserve

Phase 4

Terminated

Conditions: Hypertrophic Cardiomyopathy
Microvascular Ischaemia of Myocardium
Non-ischemic Dilated Cardiomyopathy

Interventions: Drug: Regadenoson
Drug: Adenosine

First Posted Date: 2017-08-15

Last Posted Date: 2020-09-16

Lead Sponsor: Duke University

Target Recruit Count: 31

Registration Number: NCT03249272

Locations: 🇺🇸
Duke Cardiovascular Magnetic Resonance Center, Durham, North Carolina, United States

A Dose Titration Study to Assess the Effects of SAR407899 in Patients With MVA and/or Persistent Stable Angina Despite Angiographically Successful PCI

Phase 2

Terminated

Conditions: Microvascular Coronary Artery Disease

Interventions: Drug: Placebo
Drug: SAR407899
Drug: Adenosine
Drug: Regadenoson
Drug: 13N-ammonia
Drug: 82Rubidium

First Posted Date: 2017-08-01

Last Posted Date: 2022-03-24

Lead Sponsor: Sanofi

Target Recruit Count: 10

Registration Number: NCT03236311

Locations: 🇺🇸
Investigational Site Number 8400001, Jacksonville, Florida, United States
🇺🇸
Investigational Site Number 8400013, Wellington, Florida, United States
🇩🇰
Investigational Site Number 2080001, København Nv, Denmark

and more 7 locations

Coronary Artery Vasculopathy in Pediatric Heart Transplant Patients

Phase 3

Completed

Conditions: Orthotopic Heart Transplant

Interventions: Drug: Adenosine

First Posted Date: 2017-07-27

Last Posted Date: 2017-09-26

Lead Sponsor: Bryan Goldstein

Target Recruit Count: 22

Registration Number: NCT03231371

Locations: 🇺🇸
University of MIchigan-Congenital Heart Center, Ann Arbor, Michigan, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy